Lin, Lilie L
Lakomy, David S
Ning, Matthew S
Simpkins, Fiona
Jhingran, Anuja https://orcid.org/0000-0002-0697-1815
Clinical trials referenced in this document:
Documents that mention this clinical trial
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
Documents that mention this clinical trial
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
Documents that mention this clinical trial
Targeted therapy in cervical cancer
https://doi.org/10.1136/esmoopen-2018-000462
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma
https://doi.org/10.1136/jitc-2020-000537
Documents that mention this clinical trial
Role of stereotactic body radiotherapy in gynecologic radiation oncology
https://doi.org/10.1136/ijgc-2021-002466
2022-RA-638-ESGO Pembrolizumab with multimodal immunomodulation in chemotherapy-pretreated cervical, endometrial, and uterine cancer: the PRIMMO phase II trial
https://doi.org/10.1136/ijgc-2022-esgo.401
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study
https://doi.org/10.1007/s00262-022-03253-x
Documents that mention this clinical trial
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
Documents that mention this clinical trial
Accuracy of surveillance serum squamous cell carcinoma antigen for cervical cancer recurrence after definitive chemoradiation
https://doi.org/10.1136/ijgc-2024-005303
Radiation therapy in the definitive management of medically inoperable endometrial cancer
https://doi.org/10.1136/ijgc-2021-002532
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
Documents that mention this clinical trial
ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation
https://doi.org/10.1136/ijgc-2022-003370
Concurrent chemoradiation and brachytherapy alone or in combination with nelfinavir in locally advanced cervical cancer (NELCER): study protocol for a phase III trial
https://doi.org/10.1136/bmjopen-2021-055765
CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study
https://doi.org/10.1136/ijgc-2019-001135
O001/#504 Durvalumab, in combination with and following chemoradiotherapy, in locally advanced cervical cancer: results from the phase 3 international, randomized, double-blind, placebo-controlled calla trial
https://doi.org/10.1136/ijgc-2022-igcs.3
Combined modality management of advanced cervical cancer including novel sensitizers
https://doi.org/10.1136/ijgc-2021-003137
Advances in immunotherapy for cervical cancer: recent developments and future directions
https://doi.org/10.1136/ijgc-2021-002492
Advances in immunotherapy in cervical cancer
https://doi.org/10.1136/ijgc-2022-003758
Neoadjuvant immunotherapy of locoregionally advanced solid tumors
https://doi.org/10.1136/jitc-2022-005036
Exploiting the immunogenic potential of standard of care radiation or cisplatin therapy in preclinical models of HPV-associated malignancies
https://doi.org/10.1136/jitc-2022-005752
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
Combined modality including novel sensitizers in gynecological cancers
https://doi.org/10.1136/ijgc-2021-002529
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
Documents that mention this clinical trial
Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer
https://doi.org/10.1136/ijgc-2019-001012
Advances in immunotherapy for cervical cancer: recent developments and future directions
https://doi.org/10.1136/ijgc-2021-002492
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
Combined modality including novel sensitizers in gynecological cancers
https://doi.org/10.1136/ijgc-2021-002529
Documents that mention this clinical trial
Role of stereotactic body radiotherapy in gynecologic radiation oncology
https://doi.org/10.1136/ijgc-2021-002466
Advances in immunotherapy for cervical cancer: recent developments and future directions
https://doi.org/10.1136/ijgc-2021-002492
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
Documents that mention this clinical trial
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
Documents that mention this clinical trial
Role of stereotactic body radiotherapy in gynecologic radiation oncology
https://doi.org/10.1136/ijgc-2021-002466
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
Combined modality including novel sensitizers in gynecological cancers
https://doi.org/10.1136/ijgc-2021-002529
Drug repurposing as a potential source of innovative therapies in cervical cancer
https://doi.org/10.1136/ijgc-2022-003585
Documents that mention this clinical trial
563 A phase I clinical trial of radiation therapy, durvalumab and tremelimumab in recurrent gynecologic cancer
https://doi.org/10.1136/jitc-2022-sitc2022.0563
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
Combined modality including novel sensitizers in gynecological cancers
https://doi.org/10.1136/ijgc-2021-002529
Documents that mention this clinical trial
Role of stereotactic body radiotherapy in gynecologic radiation oncology
https://doi.org/10.1136/ijgc-2021-002466
Advances in immunotherapy for cervical cancer: recent developments and future directions
https://doi.org/10.1136/ijgc-2021-002492
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
Documents that mention this clinical trial
Accuracy of surveillance serum squamous cell carcinoma antigen for cervical cancer recurrence after definitive chemoradiation
https://doi.org/10.1136/ijgc-2024-005303
Radiation therapy in the definitive management of medically inoperable endometrial cancer
https://doi.org/10.1136/ijgc-2021-002532
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
Documents that mention this clinical trial
Role of stereotactic body radiotherapy in gynecologic radiation oncology
https://doi.org/10.1136/ijgc-2021-002466
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
Combined modality including novel sensitizers in gynecological cancers
https://doi.org/10.1136/ijgc-2021-002529
Drug repurposing as a potential source of innovative therapies in cervical cancer
https://doi.org/10.1136/ijgc-2022-003585
Documents that mention this clinical trial
563 A phase I clinical trial of radiation therapy, durvalumab and tremelimumab in recurrent gynecologic cancer
https://doi.org/10.1136/jitc-2022-sitc2022.0563
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
Combined modality including novel sensitizers in gynecological cancers
https://doi.org/10.1136/ijgc-2021-002529
Documents that mention this clinical trial
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
Drug repurposing as a potential source of innovative therapies in cervical cancer
https://doi.org/10.1136/ijgc-2022-003585
Documents that mention this clinical trial
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
Documents that mention this clinical trial
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
Exploiting replicative stress in gynecological cancers as a therapeutic strategy
https://doi.org/10.1136/ijgc-2020-001277
Documents that mention this clinical trial
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
Documents that mention this clinical trial
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
Documents that mention this clinical trial
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
Documents that mention this clinical trial
Combined modality management of advanced cervical cancer including novel sensitizers
https://doi.org/10.1136/ijgc-2021-003137
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
Documents that mention this clinical trial
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
Combined modality including novel sensitizers in gynecological cancers
https://doi.org/10.1136/ijgc-2021-002529
Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.
https://doi.org/10.1200/jco.2023.41.16_suppl.5502
Documents that mention this clinical trial
Concurrent chemoradiation and brachytherapy alone or in combination with nelfinavir in locally advanced cervical cancer (NELCER): study protocol for a phase III trial
https://doi.org/10.1136/bmjopen-2021-055765
Combined modality management of advanced cervical cancer including novel sensitizers
https://doi.org/10.1136/ijgc-2021-003137
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
Chemoradiation and Image-Guided Brachytherapy Alone or in Combination With Protease Inhibitor (Nelfinavir Mesylate) in Stage III Cervical Cancer: Results From a Phase III Trial
https://doi.org/10.1200/oa-25-00088
Drug repurposing as a potential source of innovative therapies in cervical cancer
https://doi.org/10.1136/ijgc-2022-003585
Documents that mention this clinical trial
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
Documents that mention this clinical trial
Impact of hypoxia on cervical cancer outcomes
https://doi.org/10.1136/ijgc-2021-002806
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
Combined modality including novel sensitizers in gynecological cancers
https://doi.org/10.1136/ijgc-2021-002529
Drug repurposing as a potential source of innovative therapies in cervical cancer
https://doi.org/10.1136/ijgc-2022-003585
Documents that mention this clinical trial
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
Documents that mention this clinical trial
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
Documents that mention this clinical trial
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer
https://doi.org/10.1200/jco.20.02072
Documents that mention this clinical trial
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer
https://doi.org/10.1200/jco-24-01829
Documents that mention this clinical trial
Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522
https://doi.org/10.1016/j.ijrobp.2016.08.003
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
This article is maintained by: Elsevier
Article Title: Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
Journal Title: International Journal of Gynecological Cancer
CrossRef DOI link to publisher maintained version: https://doi.org/10.1136/ijgc-2020-001227
Content Type: article
Copyright: Copyright © 2020 IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.